Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RAS F3

Next Previous
Search
Drug Profile

RAS F3

Alternative Names: RAS-F; RAS-F3

Latest Information Update: 12 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Louisville
  • Developer Qualigen Therapeutics; University of Louisville
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein-protein interaction inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Lung cancer; Pancreatic cancer

Most Recent Events

  • 31 Dec 2022 Qualigen Therapeutics has patents pending for RAS F3 in USA, Europe, Australia, Canada, China, Hong Kong, India, Israel, Japan, Korea, Mexico, Russia and South Africa
  • 03 Jun 2022 Pharmacodynamics data from a preclinical trial in Pancreatic cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
  • 09 Jul 2021 Preclinical trials in Colorectal cancer in USA (unspecified route), prior to July 2021 (Qualigen pipeline, July 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top